Transcription of TNKase Dosing Card
{{id}} {{{paragraph}}}
Example: tourism industry
TNKase Dosing Card
Patient Weight (kg)Patient Weight (lb) TNKase (mg)Reconstituted (5 mg/mL) TNKase (mL)<60<13230660 to <70132 to <15435770 to <80154 to <17640880 to <90176 to <198459 90 1985010In the treatment of AMI, considerINDICATIONTNKase (tenecteplase) is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI SAFETY INFORMATIONC ontraindicationsTNKase therapy in patients with AMI is contraindicated in the following situations because of an increased risk of bleeding: active internal bleeding; history of cerebrovascular accident; intracranial or intraspinal surgery, or trauma within 2 months; intracranial neoplasm, arteriovenous malformation, or aneurysm; known bleeding diathesis; and severe uncontrolled INFORMATIONTNKase (Tenecteplase) is for intravenous administration only.
Rates of in-hospital procedures, including percutaneous transluminal coronary angioplasty (PTCA), stent placement, intra-aortic balloon pump (IABP) use, and coronary artery bypass graft (CABG) surgery, were similar between the TNKase and Activase ® (Alteplase) groups.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: